SCHEMBL16220115

SCHEMBL16220115

CC(C)(C)OC(=O)N1CCCC(c2cc(Cl)nc(Cl)n2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV3 Q8NET8 2/20 0.46
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 3/20 0.44
HPGD P15428 3/20 0.44
GLA P06280 1/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
HPGDS O60760 1/20 0.43
PRMT5 O14744 2/20 0.43
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 2/20 0.42
USP30 Q70CQ3 1/20 0.41
PDE4B Q07343 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
THRB P10828 1/20 0.40
SCN9A Q15858 1/20 0.40
GLS O94925 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16220250 0.94 KDM4E (0.46) TRPV3ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL16210779 0.90 TRPV3 (0.46) TRPV3ALDH1A1KDM4EHPGDGLA
SCHEMBL16220348 0.87 KDM4E (0.52) ALDH1A1KDM4EHPGDHSD17B10MEN1
SCHEMBL22239461 0.85 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDGLARECQL
SCHEMBL31224355 0.84 PDE4B (0.47) TRPV3ALDH1A1KDM4EHPGDGLA
SCHEMBL22123225 0.83 MAP3K12 (0.45)
SCHEMBL16220399 0.82 TRPV3 (0.41) TRPV3ALDH1A1KDM4EHPGDGLA
SCHEMBL31383603 0.82 TRPV3 (0.49) TRPV3ALDH1A1KDM4EHPGDGLA
SCHEMBL14991675 0.81 TRPV3 (0.46) TRPV3ALDH1A1KDM4EHPGDGLA
SCHEMBL21604683 0.80 ALDH1A1 (0.47) TRPV3ALDH1A1KDM4EHPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9868720-B2 C-linked heterocycloaklyl substituted pyrimidines and their uses GENENTECH, INC. (US) 2018-01-16 US disclosed
US-9868720-B2 C-linked heterocycloaklyl substituted pyrimidines and their uses GENENTECH, INC. (US) 2018-01-16 US disclosed
US-20160046608-A1 C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses GENENTECH, INC. (US) 2016-02-18 US disclosed
US-20160046608-A1 C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses GENENTECH, INC. (US) 2016-02-18 US disclosed
WO-2014177524-A1 C-LINKED HETEROCYCLOALKYL SUBSTITUTED PYRIMIDINES AND THEIR USES F. HOFFMANN-LA ROCHE AG (CH) 2014-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046608-A1 C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses TYMS, DPYD, TYMP TRPV3 4779/4885ALDH1A1 1308/4885KDM4E 2394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.